如何治愈自身免疫性肾小球疾病与足细胞病
该综述基于自身免疫性肾小球疾病与足细胞病共享的病理生理机制,提出按疾病急性程度重新划分治疗优先级:快速进展型需立即抑制补体并清除抗体,复发或慢性活动型以B细胞靶向单药长期控制免疫活动,多抗原/多克隆疾病则采用联合治疗;同时强调按KDIGO CKD风险矩阵管理肾病进展,蛋白尿水平单独不能指导治疗选择。
要点
- 按疾病急性程度而非仅蛋白尿与病理类型决定免疫治疗强度。
- 快速进展型肾小球疾病可先清除抗体再启动B细胞靶向治疗以控制新自身抗体生成。
- 单克隆自身反应性疾病适用B细胞靶向单药,多抗原/多克隆疾病适用联合治疗。
核心结论
- 按自身免疫病理机制重新定义肾小球疾病与足细胞病的治疗优先级,可明确免疫治疗选择并落实CKD管理以改善长期结局。
研究设计与样本
- 综述,基于自身免疫性肾小球疾病与足细胞病共享的病理生理机制提出治疗优先级框架。
主要发现
- 快速进展型肾小球疾病取决于所涉抗体水平与肾毒性及补体激活,可能需要立即抑制补体并在B细胞靶向治疗前清除循环抗体。
- 复发或慢性活动性疾病需以B细胞靶向单药长期控制免疫活动,适用于单个自身反应性淋巴细胞克隆。
- 多自身抗原/多克隆疾病如狼疮肾炎或抗磷脂综合征可从联合治疗中获益。
- 所有形式肾小球疾病及多数复发性足细胞病可致肾小球硬化与肾单位丢失,即CKD。
- 复发与慢性疾病中蛋白尿水平可能反映活动、CKD或两者,单凭蛋白尿不能指导治疗选择。
关键数值与推荐
- CKD管理遵循最新KDIGO CKD风险矩阵与治疗推荐。
- 复发性肾小球疾病/足细胞病中CKD管理为第二治疗优先级,慢性肾小球疾病中为第一治疗优先级。
- 单个自身反应性淋巴细胞克隆者采用B细胞靶向单药治疗。
- 多自身抗原/多克隆疾病采用联合治疗,类似肾移植。
临床怎么用
- 先评估疾病急性程度以确定治疗优先级,快速进展型优先补体抑制与抗体清除。
- 按自身反应性克隆数量选择B细胞靶向单药或联合治疗。
- 所有患者均应落实KDIGO CKD风险管理,复发性与慢性疾病中尤其重视CKD照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune GN and podocytopathies are immune-mediated kidney diseases with different clinical presentations and histotypes. Traditionally, proteinuria and histotypes are used for prognosis prediction and hence define intensity of immunotherapy. Renin-angiotensin system and sodium-glucose transporter 2 inhibitors are considered as "supportive care," and control of proteinuria seems a primary treatment goal without reasoning the cause of proteinuria. We propose to refine these concepts based on the shared pathophysiology of these diseases: ( 1 ) Disease acuity as the primary determinant of therapy. Rapidly progressive GN, relapsing GN, and chronic GN require different priorities. Rapidly progressive GN depends on the level and nephrotoxicity of the involved antibodies and complement activation and may require immediate complement inhibition, and antibody removal from the circulation before a B-cell-targeting therapy is initiated to control de novo autoantibody production. ( 2 ) Relapsing or chronically active disease need long-term control of immunologic activity with a B-cell-targeting monotherapy, in case of single autoreactive lymphocyte clones, for example, in antineutrophil cytoplasmic antibodies vasculitis or antinephrin/anti-M-type phospholipase A2 receptor-nephrotic syndrome. By contrast, diseases with numerous autoantigens/clones, i.e ., lupus nephritis or antiphospholipid syndrome should benefit from combination therapies, similar to kidney transplantation. ( 3 ) All forms of GN and most relapsing podocytopathies lead to glomerulosclerosis and nephron loss, i.e ., CKD. This implies CKD management following the latest Kidney Disease Improving Global Outcomes CKD risk matrix and treatment recommendations. In relapsing GN/podocytopathies, CKD care is the second treatment priority; in chronic GNs, it becomes the first treatment priority in contrast to "supportive care." In relapsing and chronic disease, proteinuria levels may represent activity, CKD, or both; hence, proteinuria alone does not inform treatment choices. This review aims to overcome existing hurdles by redefining treatment priorities in GNs and podocytopathies based on the underlying autoimmune pathomechanisms to define immunotherapy and by implementing CKD care for conceptual clarity and better long-term outcomes.
引用
- Anders HJ, Steiger S, Romagnani P, et al. How to Cure Autoimmune GN and Podocytopathies. J Am Soc Nephrol. 2025. PMID: 41071671. doi:10.1681/ASN.0000000912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。